Clinical trials: Neoplasia Prostate
Metastatic Prostate Cancer
Biomarkers of Bone Resorption in Metastatic Prostate Cancer
Biomarkers of bone resorption will be measured in the blood of patients with bone metastases from prostate cancer during the course of their illness.
- Trial name
- NCT01233557
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Aberdeen
Prostate Cancer Recurrent
Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer
Radiation therapy is considered a standard treatment option for the management of localized prostate cancer. Among the 20-30% of patients who recur, there is no consensus on the optimal salvage therapy.
- Trial name
- NCT02560181
- Testing
- HDR brachytherapy
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Sunnybrook Health Sciences Centre
Prostate Cancer
Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks
The purpose of this study is to determine whether using the P3P website can increase decisional preparation and satisfaction, and decrease decisional conflict, in men deciding how to manage early stage prostate cancer.
- Trial name
- NCT01844999
- Testing
- Personal Patient Profile - Prostate (P3P), Standard prostate cancer information websites
- Where
- 4 sites in United States
- Volunteers
- 392 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer, Prostate Adenocarcinoma
MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer
The hypotheses of this study are: 1. Delivery of single fraction Lattice Extreme Ablative Dose (LEAD) radiotherapy (RT) to the dominant tumor lesion(s) in the prostate as identified by multiparametric functional Magnetic…
- Trial name
- LEAD (NCT01411319)
- Testing
- Lattice Extreme Ablative Dose Radiation Therapy, Standard IMRT
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Miami
Prostate Cancer, Carcinoma of the Rectum
Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium
Postoperative cognitive dysfunction (POCD) and postoperative delirium occurs mainly in aged patients. POCD and POD may increase the mortality and morbidity.
- Conditions
- Prostate Cancer, Carcinoma of the Rectum, Colon Cancer, Renal Carcinoma
- Trial name
- MAPOCD (NCT02928692)
- Testing
- Minocycline
- Where
- 5 sites in China
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Prostate Cancer
GM-CSF for Maintenance of Prostate Cancer for Patients Responding to Taxotere
This trial is designed to investigate the efficacy and safety of GM-CSF used as a maintenance program in patients with androgen-independent prostate cancer (AIPC) who have achieved a maximal response on a taxotere or other…
- Trial name
- NCT00274287
- Testing
- GM CSF
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Oncology Specialists, S.C.
Prostate Cancer
Ultralow Versus Standard Pneumoperitoneum Pressure
The investigators plan to compare insufflation pressures during robotic assisted laparoscopic prostatectomy (RALP). Standard pressure is typically 15 mmHg, while in a previous study the investigators determined that 6 mmHg is…
- Trial name
- Ultralow (NCT03630393)
- Testing
- Pneumoperitoneum Pressure 6 mmHg, Pneumoperitoneum Pressure 15 mmHg
- Where
- United States
- Volunteers
- 170 people
- Sponsor
- OhioHealth
Prostate Cancer
High-intensity Focused Ultrasound Combined With Novel Hormone Therapy in Advanced Prostate Cancer
The goal of this clinical trial is to explore the feasibility and the synergistic anti-cancer effect of high-intensity focused ultrasound (HIFU) combined with novel hormone therapy (NHT) in advanced prostate cancer (PCa).
- Trial name
- HIFU NHT PCa (NCT07126093)
- Testing
- focal high-intensity focused ultrasound therapy combined with standard novel hormonal therapy, Standard novel hormonal therapy only
- Volunteers
- 134 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Prostate Cancer Early Risk Treated by Radiosurgery, Prostate Cancer Intermediate Risk Treated by Radiosurgery
Multi-Institutional Registry for Prostate Cancer Radiosurgery
To address pertinent questions regarding the utilization of stereotactic Body Radiotherapy (SBRT) to treat prostate cancer. The Florida Robotic Radiosurgery Association (FRRA) launched the first registry for prostate cancer…
- Trial name
- RPCR (NCT01226004)
- Where
- 44 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- RPCR, Inc.
Prostate Cancer
Prostate Advances in Comparative Evidence
This study is an international multicentre randomised study of low, intermediate, and high risk prostate cancer and is composed of three parallel randomisation schemes based on applicability of surgery as a treatment for the…
- Trial name
- PACE (NCT01584258)
- Testing
- Prostatectomy, Conventionally Fractionated Prostate Radiotherapy, Prostate SBRT
- Where
- 68 sites in Canada, Ireland and 2 more
- Volunteers
- 2,205 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Prostate Cancer
Comparison of a Novel Leuprolide With Market Leuprolide
This is a single dose, randomized, single blind, parallel group study to evaluate the testosterone suppressive effect in healthy male volunteers of a novel leuprolide acetate 3.75mg depot vs market reference leuprolide acetate…
- Trial name
- NCT03662958
- Testing
- Lutrate, Enantone
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Prostate Cancer
High-resolution Intra-operative PSMA PET-CT in Prostate Cancer
This is a Single-center, diagnostic open-label prospective, pilot study in a total of 10 patients affected by Prostate cancer (PCa) with a risk of lymph node invasion (LNI) higher than 5% and candidates for a robot-assisted…
- Trial name
- NCT06298838
- Testing
- AURA10® Specimen PET/CT imager
- Volunteers
- 10 people
- Sponsor
- IRCCS San Raffaele
Patients With Suspected Prostate Cancer
Multicentric Comparative Prospective Study of the Benefits and Risks of Biopsy Prostate Using Transrectal or Transperineal Procedure for the Prostate Cancer Diagnostic
The performance of prostatic biopsies is an essential element to confirm the diagnosis of prostate cancer and to specify the characteristics of the tumor in terms of stage and grade.
- Trial name
- BIOPROSTABORD (NCT05763355)
- Testing
- Biopsy
- Where
- 2 sites in France
- Volunteers
- 101 people
- Sponsor
- Elsan
Prostate Cancer
Reiki/Energy Healing in Prostate Cancer
The purpose of this study is to determine whether Reiki energy healing affects anxiety and disease progression in patients with localized prostate cancer who are candidates for radical prostatectomy.
- Trial name
- NCT00065208
- Testing
- Reiki, Pretend Reiki, Rest / Guided Imagery
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- The Cleveland Clinic
Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer
PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer
The goal of this clinical trial is to learn if serial PSMA-PET/CT scans can be used to monitor response to therapy in metastatic hormone sensitive prostate cancer and can be potentially used to optimize future treatment…
- Conditions
- Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT06479187
- Testing
- 18F-rhPSMA-7.3, PET/CT
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Prostate Cancer
Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer
The investigators are trying to find new methods to treat prostate cancer. The approach is to try to enhance patients' own immune response against the cancer.
- Trial name
- NCT00849121
- Testing
- pTVG-HP with rhGM-CSF
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer
The study is an open-label Phase 1 study of the combination of relacorilant with enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).
- Trial name
- NCT03674814
- Testing
- Enzalutamide, Relacorilant
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- University of Chicago
Squamous Cell Carcinoma of the Head and Neck (SCCHN), Metastatic Castration Resistant Prostate Cancer (mCRPC)
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or…
- Trial name
- NCT04052204
- Testing
- avelumab, Bempegaldesleukin, talazoparib
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 3 people
- Sponsor
- Pfizer
Prostate Cancer, Advanced Renal Cell Carcinoma
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
This is a tissue and blood collection protocol requiring image-guided biopsies of metastatic prostate cancer and other genitourinary malignancies including renal cell carcinoma and urothelial carcinoma.
- Conditions
- Prostate Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Carcinoma, Genitourinary Cancer
- Trial name
- NCT02735252
- Testing
- Systemic therapy, StrataNGS
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- University of California, San Francisco
Metastatic Breast Cancer, Metastatic Prostate Cancer
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
The REaCT-CHRONO-MetBP Pilot study will compare morning and evening administration of endocrine-based therapy in metastatic breast and prostate cancers.
- Trial name
- NCT07252726
- Testing
- Morning administration of CDK4/6 inhibitor, Evening administration of CDK4/6 inhibitor, Morning administration of ARPI
- Where
- 3 sites in Canada
- Volunteers
- 50 people
- Sponsor
- Ottawa Hospital Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.